These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Cost-effectiveness data on biologics needed. Sheridan C; Katsnelson A Nat Biotechnol; 2005 Mar; 23(3):272-3. PubMed ID: 15765069 [No Abstract] [Full Text] [Related]
26. The 340B Drug Pricing Program: an opportunity for savings, if covered entities such as disproportionate share hospitals and federally qualified health centers know how to interpret the regulations. Werling K; Abraham S; Strelec J J Health Care Finance; 2007; 34(2):57-70. PubMed ID: 18972994 [No Abstract] [Full Text] [Related]
27. [The cost of innovative drugs]. Reggio S Recenti Prog Med; 1999; 90(7-8):371-2. PubMed ID: 10429514 [No Abstract] [Full Text] [Related]
28. How NICE may be outflanked. Ferner RE; McDowell SE BMJ; 2006 May; 332(7552):1268-71. PubMed ID: 16735342 [No Abstract] [Full Text] [Related]
29. Pharmaceutical industry financial performance. Goodman M Nat Rev Drug Discov; 2009 Dec; 8(12):927-8. PubMed ID: 19949398 [No Abstract] [Full Text] [Related]
31. Sir Michael Rawlins on being NICE--and fair--about drug development and availability. Interview by Daniel Clarke. Rawlins SM Drug Discov Today; 2005 Mar; 10(6):383-6. PubMed ID: 15808816 [No Abstract] [Full Text] [Related]
32. Clinical trials and health economics--a marriage of convenience or a marriage made in heaven? Bakhai A; Greenberg D J Med Econ; 2008; 11(3):541-6. PubMed ID: 19450103 [No Abstract] [Full Text] [Related]
34. What's driving up health insurance cost now? Batterson RE Tex Dent J; 2003 Mar; 120(3):288-91. PubMed ID: 12723113 [No Abstract] [Full Text] [Related]
35. Spiraling drug costs: a call for cost-effective prescribing. Good CB J Am Geriatr Soc; 2005 Aug; 53(8):1427-9. PubMed ID: 16078975 [No Abstract] [Full Text] [Related]
36. Priced out of the UK market. Moran N Nat Biotechnol; 2008 Feb; 26(2):151-4. PubMed ID: 18259163 [No Abstract] [Full Text] [Related]
37. [TLV meets criticism: costs of antihypertensive agents can and should be reduced]. Edling A; Löfmark R; Vinge E; Carlsson P; André M; Melltorp G; Edhag O; Dahlqvist R; Andersson I; Magnusson D Lakartidningen; 2008 Sep 17-23; 105(38):2592-3. PubMed ID: 18846865 [No Abstract] [Full Text] [Related]
38. [Can drug consumption in general be reduced and can drug costs for insurance carriers be reduced?]. TOELKE S Pharm Prax; 1959; 10():149-53. PubMed ID: 13838637 [No Abstract] [Full Text] [Related]
40. "Who's winning the human race?"Cold war as pharmaceutical political strategy. Tobbell DA J Hist Med Allied Sci; 2009 Oct; 64(4):429-73. PubMed ID: 19493917 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]